Literature DB >> 16206268

Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells.

Daniela Baus1, Edith Pfitzner.   

Abstract

The essential regulators in the pathogenesis of classical Hodgkin lymphoma (cHL) are still largely unknown. The malignant Hodgkin/Reed-Sternberg (HRS) cells of cHL secrete various cytokines leading to the activation of signaling pathways such as the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. In this study, we investigate the role of distinct JAK/STAT pathway components in the regulation of proliferation and survival of cHL cell lines. Electrophoretic mobility shift assay and western blot analysis revealed that the activation status of STAT family members varies in different cHL cell lines. Tyrosine kinase inhibitors of the JAK/STAT pathway blocked the activation of most of the STAT family members. This was accompanied with a strong antiproliferative effect and enhanced death of the treated cHL cell lines. Specific downregulation of STAT3 by siRNA expression decreased cell proliferation and induced apoptosis. Overexpression of SOCS1 and SOCS3 resulted in a proliferation arrest of cells with limited endogenous amount of these negative regulators, but not in cells that already express high amounts of SOCS1 and SOCS3. Our findings highlight the importance of STAT3 in cHL transformation and suggest SOCS1 and SOCS3 as potential targets for therapeutic intervention in distinct forms of cHL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16206268     DOI: 10.1002/ijc.21539

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

Review 1.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

2.  Acetylation of Stat1 modulates NF-kappaB activity.

Authors:  Oliver H Krämer; Daniela Baus; Shirley K Knauer; Stefan Stein; Elke Jäger; Roland H Stauber; Manuel Grez; Edith Pfitzner; Thorsten Heinzel
Journal:  Genes Dev       Date:  2006-02-15       Impact factor: 11.361

3.  The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.

Authors:  Daniela Buglio; Vidya Mamidipudi; Noor M Khaskhely; Helen Brady; Carla Heise; Jeffrey Besterman; Robert E Martell; Kyle MacBeth; Anas Younes
Journal:  Br J Haematol       Date:  2010-09-29       Impact factor: 6.998

Review 4.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

Review 5.  [Lymph node pathology - an update].

Authors:  S Hartmann; M L Hansmann
Journal:  Pathologe       Date:  2013-02       Impact factor: 1.011

6.  Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines.

Authors:  Daniela Buglio; Georgios V Georgakis; Shino Hanabuchi; Kazuhiko Arima; Noor M Khaskhely; Yong-Jun Liu; Anas Younes
Journal:  Blood       Date:  2008-06-09       Impact factor: 22.113

Review 7.  Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas.

Authors:  Emily C Brantley; Etty N Benveniste
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

8.  Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma.

Authors:  Wei Ju; Meili Zhang; Kelli M Wilson; Michael N Petrus; Richard N Bamford; Xiaohu Zhang; Rajarshi Guha; Marc Ferrer; Craig J Thomas; Thomas A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-25       Impact factor: 11.205

9.  Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma.

Authors:  Amit Sud; Hauke Thomsen; Giulia Orlando; Asta Försti; Philip J Law; Peter Broderick; Rosie Cooke; Fadi Hariri; Tomi Pastinen; Douglas F Easton; Paul D P Pharoah; Alison M Dunning; Julian Peto; Federico Canzian; Rosalind Eeles; ZSofia Kote-Jarai; Kenneth Muir; Nora Pashayan; Daniele Campa; Per Hoffmann; Markus M Nöthen; Karl-Heinz Jöckel; Elke Pogge von Strandmann; Anthony J Swerdlow; Andreas Engert; Nick Orr; Kari Hemminki; Richard S Houlston
Journal:  Blood       Date:  2018-09-07       Impact factor: 22.113

10.  HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells.

Authors:  Nils Schoof; Frederike von Bonin; Lorenz Trümper; Dieter Kube
Journal:  Cell Commun Signal       Date:  2009-07-16       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.